Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Diatos logo — Pioneering advancements in cancer treatment through innovati...

Diatos

Pioneering advancements in cancer treatment through innovative drug targeting and enhanced biodistribution.

Founded 1999 Series D Total: $12.80M Biotechnology

General Information

Company Name Diatos
Founded Year 1999
Industries Biotechnology
Funding Stage Series D
Social

BounceWatch is an independent company data service, not affiliated with Diatos. To contact Diatos, visit diatos.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Diatos compare?

A PDF of Diatos and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Diatos soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Diatos

Diatos is a pioneering biopharmaceutical company founded in 1999 based in Paris, France, with subsidiaries in Leuven, Belgium, and the San Francisco Bay Area, USA. Specializing in biotechnology, the company focuses on advancing cancer treatment through innovative drug targeting and enhanced biodistribution. It has developed advanced versions of existing anti-cancer chemotherapeutic drugs that offer improved tumor targeting or enhanced biodistribution, leveraging its proprietary prodrug technologies, Vectocell® and Tumor-Selective Prodrug (TSP). Diatos has expanded its drug portfolio through license acquisitions and internal research and development. The company's latest funding round was a $12.80M Series D investment on 03 July 2007, with contributions from IDInvest Partners, InterWest Partners, Sofinnova Partners, GIMV, Credit Agricole Entreprises, Sopartec, NIF SMBC Ventures, Biotech Fund Flanders, Innoven Partners, Societe Generale Asset Management.

Business keywords: biopharmaceutical, cancer treatment, drug targeting, biodistribution, chemotherapeutic drugs, anti-cancer, prodrug technologies, tumor targeting, license acquisitions, Paris, France, Leuven, Belgium, San Francisco Bay Area, oncology, innovation

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Series D $12.80M 10
IDInvest Partners InterWest Partners Sofinnova Partners
IDInvest Partners, InterWest Partners +8
03 Jul 2007

Diatos Alternatives & Competitors

View All Alternatives
Diatos vs
Cage Pharma
Cage Pharma

Innovative pre-clinical biopharma advancing tumor-targeting therapies with groundbreaking encapsulat...

Venture round
0-1 employees
Biopharma, Biotechnology
Diatos vs
Epsilogen Ltd
Epsilogen Ltd United Kingdom

Harnessing the power of IgE

Series B
33 employees
Biopharma, Biotechnology
Diatos vs
Agensys
Agensys

Pioneering advanced treatments for cancer with innovative therapeutic antibodies and drug conjugates...

Series D
Biotechnology, Health Care
View all alternatives

FAQ About Diatos

Pioneering advancements in cancer treatment through innovative drug targeting and enhanced biodistribution.
Diatos was founded in 1999.
Diatos operates in Biotechnology. Its work centres on biopharmaceutical, cancer treatment, drug targeting and biodistribution.
Diatos has completed 1 funding round, raising a total of $12.80M. The latest funding stage is Series D.
Top alternatives and competitors to Diatos include Cage Pharma, Epsilogen Ltd, Agensys, Duo Oncology, Tempest Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Diatos and Cage Pharma are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Diatos, https://bouncewatch.com/company/diatos, updated 10 October 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes